Drug General Information (ID: DDIM6G29ND)
Drug Name			Thioridazine		Drug Info		Fostemsavir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antipsychotic Agents				Antiviral Agents
Structure

Mechanism of Thioridazine-Fostemsavir Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Thioridazine				Fostemsavir
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Thioridazine and Fostemsavir

Recommended Action
Management		Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Liberatore MA, Robinson DS "Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?" J Clin Psychopharmacol 4 (1984): 143-6. [PMID: 6145728]
3	Product Information. Mellaril (thioridazine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.